- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02791555
Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers
Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
1.0 Hypothesis: The direct thrombin inhibitor Pradaxa positively affects bone turnover markers and increases bone mineral density in women and men at risk for osteoporosis.
2.0 Goal: The goal of this study is to establish if the direct thrombin inhibitor Pradaxa positively affects bone turnover markers and increases bone mineral density in women and men at risk for osteoporosis.
3.0 Specific Aims.
3.1 To determine the effect of Pradaxa on bone mineral density in patients after 6 and 12 months of daily use.
3.2 To determine the effect of the direct thrombin inhibitor Pradaxa on bone turnover markers for osteoclastic resorption (measured as serum levels of C-terminal peptide, and N-telopeptide) and osteoblastic formation (measured as serum levels of bone-specific alkaline phosphatase, osteocalcin and P1NP) in subjects after 6 and 12 months of daily use.
3.3 To evaluate any correlation among the hemoclot, thrombin inhibitor test, changes in markers of bone turnover and changes in bone mineral density in patients on Pradaxa.
3.4 To determine the effect of Pradaxa on change in serum levels of receptor activator of NF B-ligand (RANKL), osteoprotegerin (OPG), RANKL/OPG ratio, inflammatory markers (IL-1b, IL-6, TNF-alpha and FGF-23) and inhibitors of Wnt/beta-catenin signaling pathway including sclerostin and DKK1 at baseline, 6 and 12 months, to understand the mechanisms for the effect of Pradaxa on bone.
4.0 Study design and procedures.
4.1 Study Design:
This will be a prospective, Phase IV age-matched cohort study in men and women who are being started on long-term treatment with Pradaxa for nonvalvular atrial fibrillation. This is a proof of concept study evaluating the effect of Pradaxa, a direct thrombin inhibitor on bone density and bone turnover markers in comparison to warfarin.
4.2 Subject Population:
The investigators will be recruiting patients with nonvalvular atrial fibrillation who are being prescribed Pradaxa by their cardiologists or primary care providers for long-term anticoagulant treatment for participation in the study. The patients taking Pradaxa will be the study group, and will be compared to an age-matched cohort of men and women with nonvalvular atrial fibrillation who are being started on long-term warfarin by their cardiologists or primary care providers (control group). The investigators will be evaluating 20 men and 20 women in the Pradaxa cohort and another age-matched 20 men and 20 women in the warfarin cohort (Pradaxa cohort: N = 40, 20 men, 20 women; Warfarin cohort: N = 40, 20 men, 20 women). The two groups will be determined based on treatment assigned to them by their cardiologists or primary care providers. As age can influence the risk for osteoporosis, the warfarin group will be age-matched to the Pradaxa group for optimal comparison. This will be achieved by offering participation to patients taking warfarin who are similar in age to the patients being recruited for the Pradaxa group. As women are more likely to develop osteoporosis and the effects of Pradaxa may be gender-based as a result of differences in the levels of sex hormones, the investigators are evaluating a cohort of men and women in this pilot study for comparison.
The investigators expect to see an older cohort of subjects with atrial fibrillation, who are also likely to have an increased risk of osteoporosis.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Connecticut
-
Farmington, Connecticut, Stati Uniti, 06030
- University of Connecticut Health Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age 50 and above, male and female starting on Pradaxa or Warfarin for nonvalvular atrial fibrillation
- Able to ambulate independently and travel to UConn Health in Farmington CT-
Exclusion Criteria:
- Prior known history of osteoporosis
- Chronic kidney disease with creatinine clearance less than 30
- Serum 25 hydroxyvitamin D level less than 10
- Ongoing treatment with medications that interfere with bone metabolism such as steroids, bisphosonates, denosumab, estrogen, SERMS
- Hypercalcemia, a history of Paget's disease, a history of multiple myeloma, or a history of monoclonal gammopathy of uncertain significance -
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Pradaxa
20 men and 20 women on Pradaxa for non valvular atrial fibrillation
|
Warfarin
20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in bone mineral density in patients
Lasso di tempo: 6 and 12 months
|
Measurement of bone density using DXA
|
6 and 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in bone turnover markers
Lasso di tempo: 6 and 12 months
|
Serum C-terminal and N- terminal telopeptide, Bone specific alkaline phosphatase, osteocalcin and P1NP
|
6 and 12 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Joseph Lorenzo, MD, UConn Health
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 16-115-1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .